This revived the quest for targeting KRAS which ultimately resulted in FDAapproval in 2021 for the first KRASi sotorasib for the treatment of NSCLC patients carryingKRASG12C mutation [21], followed by approval for thesecond KRASi adagrasib the very next year [22].Despite advances in targeting KRAS oncoprotein achieved by the clinical development ofKRASG12Ci, PDAC patients are miles away from being benefitted by such promising therapies.Although KRAS mutations are present in 93% of PDAC patients, KRASG12C accounts for less than2% of them. This evidence concerns the gene KRAS and non-small cell lung carcinoma.